Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics
| Autor: | Glenn E. Dale, Michael M. Tunney, María Díez-Aguilar, Deirdre Gilpin, J. Stuart Elborn, Ad C. Fluit, Jumamurat R. Bayjanov, Francesca Bernardini, Miquel B. Ekkelenkamp, Rafael Cantón |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Imipenem
Cystic Fibrosis Ceftazidime Microbial Sensitivity Tests Aztreonam Biology medicine.disease_cause Peptides Cyclic Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Drug Resistance Multiple Bacterial Drug Resistance Bacterial polycyclic compounds medicine Tobramycin Humans Pseudomonas Infections Pharmacology (medical) Pharmacology 0303 health sciences 030306 microbiology Pseudomonas aeruginosa Respiratory infection biochemical phenomena metabolism and nutrition bacterial infections and mycoses Anti-Bacterial Agents Infectious Diseases 030228 respiratory system chemistry Susceptibility Amikacin Colistin Multilocus Sequence Typing medicine.drug |
| Zdroj: | Antimicrob Agents Chemother |
| ISSN: | 1098-6596 0066-4804 |
| DOI: | 10.1128/aac.01541-19 |
| Popis: | The objective was to determine the in vitro antimicrobial susceptibility of Pseudomonas aeruginosa isolates cultured from cystic fibrosis (CF) patients and explore associations between strain sequence type and susceptibility. Fourteen antibiotics and antibiotic combinations, including the novel antibacterial peptide murepavadin, were tested for activity against 414 Pseudomonas aeruginosa isolates cultured from respiratory samples of CF patients. The complete genomes of the isolates were sequenced, and minimum spanning trees were constructed based on the sequence types (STs). Percentages of resistance according to CLSI 2019 breakpoints were as follows: cefepime, 14%; ceftazidime, 11%; ceftazidime-avibactam, 7%; ceftolozane-tazobactam, 3%; piperacillin-tazobactam, 12%; meropenem, 18%; imipenem, 32%; aztreonam, 23%; ciprofloxacin, 30%; gentamicin, 30%; tobramycin, 12%; amikacin, 18%; and colistin, 4%. Murepavadin MIC(50) and MIC(90) were 0.12 mg/liter and 2 mg/liter, respectively. There were no apparent clonal clusters associated with resistance, but higher MICs did appear to occur more often in STs with multiple isolates than in single ST isolates. In general, the CF isolates showed a wide genetic distribution. P. aeruginosa CF isolates exhibited the lowest resistance rates against ceftolozane-tazobactam, ceftazidime-avibactam, and colistin. Murepavadin demonstrated the highest activity on a per-weight basis and may therefore become a valuable addition to the currently available antibiotics for treatment of respiratory infection in people with CF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|